AbbVie Inc.

ABBV · NYSE

Official-source baseline for AbbVie using SEC submissions, FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, FY2025 results exhibit, proxy materials, annual meeting results, debt filings, and official peer filings.

Follow Add to Watchlist Ask Question

NYSE ABBV Coverage Bootstrap Pharmaceuticals Biopharmaceuticals Healthcare

Latest ReportMay 13, 2026AbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

NYSEBiopharmaceuticals

Clear tags

MatchAny tag All tags

Latest Thesis

AbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after Humira

May 13, 2026Research reportSlides available

Read report Open slides Discussion (0)

AbbVie Inc.Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharmaMay 13, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

AbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraOfficial-source baseline for AbbVie using SEC submissions, FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, FY2025 results exhibit, proxy materials, annual meeting results, debt filings, and official peer filings.NYSEMay 13, 2026Research reportRead Slides